Summary & Overview
HCPCS J2359: Injection, olanzapine 0.5 mg
HCPCS Level II code J2359 denotes an injectable dose of olanzapine, 0.5 mg. This code identifies a short-acting antipsychotic medication administered by injection, typically used in acute care or outpatient psychiatric settings. Nationally, accurately coding for injectable psychotropic medications matters for clinical documentation, payer coverage determinations, and aggregation of utilization data for behavioral health services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and which payers are relevant for coverage and claims processing. The publication outlines common modifiers associated with injectable drug administration and lists where data was not provided.
The report provides benchmarks and context useful for billing, claims reconciliation, and operational planning: pricing and allowable trends where available, payer-specific coverage considerations, and billing practice implications for outpatient and emergency settings. Clinical context explains the medication form and use case for short-acting olanzapine injections. Data not available in the input is clearly noted where applicable, and readers will receive a focused reference for coding and administrative handling of HCPCS Level II code J2359.
Billing Code Overview
HCPCS Level II code J2359 represents an injection of olanzapine, 0.5 mg. The service is a pharmacologic injectable administration of the antipsychotic agent olanzapine in a 0.5 mg dose. Typical site of service for this medication is outpatient clinical settings, including psychiatric clinics, emergency departments, and other ambulatory care settings where short-acting injectable antipsychotic medication is administered.
Service type: Medication injection / drug administration
Typical site of service: Outpatient clinic, emergency department, or ambulatory care setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acute agitation, severe psychomotor agitation, or an acute psychotic episode requiring intramuscular antipsychotic administration for rapid symptom control. The patient may present to an emergency department, psychiatric emergency service, or an inpatient psychiatric unit after escalation of agitation that poses a risk to self or others. A clinician (emergency physician, psychiatrist, or psychiatric nurse practitioner) assesses airway, breathing, circulation, vital signs, and mental status, documents the indication for rapid tranquilization, reviews medication allergies and current medications, and obtains informed consent when feasible. Nursing prepares and administers J2359 (olanzapine injection) in the recommended dose increments, monitors for adverse effects (excess sedation, respiratory depression, orthostatic hypotension, extrapyramidal symptoms), and documents medication lot number, route, dose, and postadministration observations. Depending on clinical response, additional supportive measures, observation, or transition to oral antipsychotic therapy may follow. Typical site of service includes the emergency department, inpatient psychiatric unit, observation unit, or behavioral health crisis center. Service type: single-dose intramuscular injection for acute management of agitation/psychosis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day |